home > about us > background
Background
Simcyp Limited was founded in 2001 by Professor Geoff Tucker (Chairman), Professor Amin Rostami-Hodjegan (Director of Scientific Development) and Mr John Evans (Managing Director) as a spin-out company from the University of Sheffield. Since its inception, Simcyp has continued to provide essential support in the development of new pharmaceutical agents.
Simcyp develops a user-friendly platform designed specifically to allow you to conduct simulations in representative virtual patient populations based on your in vitro data. The Simulator includes extensive demographic, physiologic and genomic databases which have allowed us to develop algorithms which account for patient variability. This enables the user to predict drug behaviour in the virtual patient population, as opposed to a virtual reference man, allowing individuals at extreme risk to be identifed.
This pioneering work led to Professor Tucker and Dr Rostami-Hodjegan being jointly awarded the New Safer Medicines Faster Award 2004 by the European Federation for Pharmaceutical Sciences (EUFEPS).
The success of Simcyp is founded on the company maintaining the Simcyp Consortium. Members of the Consortium not only gain access to Simcyp’s predictive pharmacokinetic products and consultancy services, but are also able to guide the direction of the future development of the services which Simcyp offer. The Consortium includes leading pharmaceutical and biotechnology companies, regulatory institutions and academic centres. Simcyp is also supported by a world-renowned Scientific Advisory Board.
Simcyp is continuing to expand, developing long-term contacts with global pharmaceutical companies, academic institutes and regulatory authorities.